CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
CNS Pharmicals将参与虚拟投资者午休时间：CNSP的机会
Download as PDF April 22, 2024 12:00am EDT
以 PDF 格式下载 美国东部时间 2024 年 4 月 22 日上午 12:00
Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ET
4月23日星期二与首席执行官约翰·克利马科进行网络视频直播第三方 美国东部时间下午 12:00
HOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor Lunch Break: The CNSP Opportunity event on Tuesday, April 23,2024 at 12:00 PM ET.
德克萨斯州休斯敦/ACCESSWIRE /2024年4月22日/ CNS 制药公司（纳斯达克股票代码：CNSP） （“CNS” 或 “公司”）是一家专门开发大脑和中枢神经系统原发性和转移性癌症新疗法的生物制药公司，今天宣布， 约翰·克利马科，首席执行官 的CNS制药公司将出席 虚拟投资者午休：CNSP 机会 4月23日星期二的活动，美国东部时间2024年中午12点。
As part of the event, Mr. Climaco will provide a corporate overview, business outlook and discuss the CNS opportunity. Additionally, interested parties will have the opportunity to submit questions live during the event. Mr. Climaco will answer as many questions as possible.
作为活动的一部分，Climaco先生将提供公司概述、业务展望并讨论CNS的机会。此外，感兴趣的各方将有机会在活动期间现场提交问题。Climaco 先生将回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
A 网络视频直播 演示文稿将在 活动 的页面 投资者 公司网站的部分（cnspharma.com）。网络直播重播将在现场演示结束两小时后提供，并将在90天内播放。
About CNS Pharmaceuticals, Inc.
关于 CNS Pharmicals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
CNS Pharmicals是一家临床阶段的制药公司，正在开发一系列抗癌候选药物，用于治疗脑和中枢神经系统的原发性和转移性癌症。该公司的主要候选药物贝鲁比星是一种新型的蒽环素，也是第一种似乎穿过血脑屏障的蒽环素。贝鲁比星目前正在开发中，用于治疗许多严重的脑部和中枢神经系统肿瘤适应症，包括多形性胶质母细胞瘤（GBM），这是一种侵袭性且无法治愈的脑癌。
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
欲了解更多信息，请访问 www.cnspharma.com，并通过以下方式与公司联系 推特， Facebook，以及 领英。
CONTACTS:
联系人：
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
投资者关系联系人
JTC Team, LLC
珍妮·托马斯
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
来源：CNS Pharmicals, Inc.
Released April 22, 2024
2024 年 4 月 22 日发布